Vaccitech: Funding, Investors & Team (Oct 2026)
Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centers in the world. The company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. Viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. The underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. The company’s protected chimpanzee adenovirus technology is the best way to generate T-cell responses and thereby generate lasting cell-mediated immunity. The assets are already in the clinic with very promising initial results. The founders of the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills with regulatory and manufacturing experience. This autumn, Vaccitech will begin a phase IIB efficacy study for a universal influenza vaccine in the over 65 population, and an extended phase I prostate cancer trial.
Vaccitech has raised $168M across 1 funding round on record, the most recent a Series B of $168M announced in Mar 2021.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Vaccitech Company Profile and Key Stats
Latest funding round on record: Mar 2021.
Vaccitech Funding Rounds
Vaccitech Founders and Leadership Team
Contact details for the Vaccitech team: 1 of 1 has an email address on file.
Start 14-day free trial →Vaccitech Funding Compared to Other Biotechnology Startups
Vaccitech's latest round of $168M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vaccitech in Biotechnology and Oxford
Companies Similar to Vaccitech
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Vaccitech Funding FAQs
What does Vaccitech do?
Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centers in the world. The company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. Viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. The underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. The company’s protected chimpanzee adenovirus technology is the best way to generate T-cell responses and thereby generate lasting cell-mediated immunity. The assets are already in the clinic with very promising initial results. The founders of the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills with regulatory and manufacturing experience. This autumn, Vaccitech will begin a phase IIB efficacy study for a universal influenza vaccine in the over 65 population, and an extended phase I prostate cancer trial.
How much funding has Vaccitech raised?
Vaccitech has raised $168M across 1 round on record. The most recent is a Series B of $168M announced in Mar 2021.
When did Vaccitech last raise funding?
Vaccitech's most recent funding round on record is a Series B of $168M, announced in Mar 2021.
Who is the CEO of Vaccitech?
Bill Enright is listed as CEO at Vaccitech.
Where is Vaccitech headquartered?
Vaccitech is based in Oxford, Oxfordshire, United Kingdom.
How many employees does Vaccitech have?
Vaccitech is in the 11-50 employee band.
How does Vaccitech's funding compare to other Biotechnology startups?
Vaccitech's latest round of $168M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Vaccitech Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vaccitech is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.